The LIN28B/let-7 axis is a novel therapeutic pathway in multiple myeloma
نویسندگان
چکیده
منابع مشابه
Novel therapeutic targets in multiple myeloma.
Multiple myeloma (MM) is a disorder of clonal plasma cells that accumulate in the bone marrow and secrete a monoclonal protein detectable in the blood and/or urine. In the last decade, the outcome of patients with MM has markedly improved owing to the introduction of agents such proteasome inhibitors (bortezomib) and immunomodulatory drugs (thalidomide, lenalidomide) as induction, consolidation...
متن کاملUnderstanding novel therapeutic agents for multiple myeloma.
Multiple myeloma, a B cell malignancy of the plasma cells, remains incurable. Advances in high-dose chemotherapy and stem cell transplantation have improved overall survival and event-free disease periods, but relapses are inevitable. New therapeutic agents have shown promising clinical use in patients with relapsed or refractory multiple myeloma. This article discusses the therapeutic applicat...
متن کاملRetraction: Fatty acid synthase is a novel therapeutic target in multiple myeloma
This study investigated the biological significance of the inhibition of fatty acid synthase (FAS) in multiple myeloma (MM) using the small molecule inhibitor Cerulenin. Cerulenin triggered growth inhibition in both MM cell lines and MM patient cells, and overcame the survival and growth advantages conferred by interleukin-6, insulin-like growth factor-1, and bone marrow stromal cells. It induc...
متن کاملLYMPHOID NEOPLASIA PI3K/p110 is a novel therapeutic target in multiple myeloma
In this study, we demonstrate expression and examined the biologic sequelae of PI3K/p110 signaling in multiple myeloma (MM). Knockdown of p110 by small interfering RNA caused significant inhibition of MM cell growth. Similarly, p110 specific small molecule inhibitor CAL-101 triggered cytotoxicity against LB and INA-6 MM cell lines and patient MM cells, associated with inhibition of Akt phosphor...
متن کاملTherapeutic Advancements in Multiple Myeloma
Multiple myeloma survival has significantly improved in the latest years due to a broad spectrum of novel agents available for treatment. The introduction of thalidomide, bortezomib, and lenalidomide together with autologous stem-cell transplantation has considerably increased complete remission rate and progression-free survival resulting ultimately in prolonged survival in myeloma patients. M...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Leukemia
سال: 2016
ISSN: 0887-6924,1476-5551
DOI: 10.1038/leu.2016.296